MINNEAPOLIS / Mar 01, 2023 / Business Wire / Bright Health Group, Inc. (“Bright Health” or the “Company”) (NYSE: BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported financial results for its fourth quarter and full year ended December 31, 2022.
“The Fourth Quarter and Fiscal Year of 2022 marked a year of significant transition, as we focus on our continuing business, which is anchored by our Consumer Care and Bright HealthCare segments, and successfully exit our ACA insurance business,” said Mike Mikan, President and CEO of Bright Health Group. “While we recognize the significant work ahead of us, we have conviction in our go-forward strategy. We are taking actions to best position the business for capital efficient, long-term growth as we work to build a strong foundation with value-driven care. We are also taking early, but meaningful, steps to refocus and simplify our business, while we are gaining more certainty on the final obligations for our discontinued operations and strengthening our capital position.”
“As we continue to expand our refined model, we are confident that the continuing business is well-suited to capitalize on both the market environment as it stands today and the significant future upside of the industry,” added Mr. Mikan. “Most importantly, none of this would be possible without our dedicated team. In the face of a challenging year, we are grateful for their unwavering commitment to our mission, making healthcare right, together.”
Key Metrics
| As of December 31, | ||
| 2022 |
| 2021 |
Consumer and Patient Metrics |
|
|
|
Bright HealthCare Commercial Consumers | 1,020,000 |
| 610,000 |
Bright HealthCare Medicare Advantage Consumers | 125,000 |
| 117,000 |
Consumer Care Value-Based Consumers | 530,000 |
| 170,000 |
| Three Months Ended |
| Twelve Months Ended | ||||||||||||
($ in thousands) | December 31, |
| December 31, | ||||||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 | ||||||||
Financial Metrics |
|
|
|
|
|
|
| ||||||||
Revenue | $ | 551,425 |
|
| $ | 380,223 |
|
| $ | 2,412,030 |
|
| $ | 1,513,033 |
|
Medical Cost Ratio - Bright HealthCare(1) |
| 100.1 | % |
|
| 96.9 | % |
|
| 93.9 | % |
|
| 97.3 | % |
Operating Cost Ratio |
| 33.7 | % |
|
| 49.4 | % |
|
| 26.2 | % |
|
| 34.9 | % |
GAAP Net Loss(2) | $ | (668,561 | ) |
| $ | (816,165 | ) |
| $ | (1,359,880 | ) |
| $ | (1,178,365 | ) |
Adjusted EBITDA (non-GAAP) | $ | (108,516 | ) |
| $ | (121,071 | ) |
| $ | (233,489 | ) |
| $ | (321,317 | ) |
(1) | Medical Cost Ratio for Bright HealthCare for the three months ended December 31, 2022 and 2021, include a 210 basis point and 290 basis point, respectively, unfavorable impact from COVID-19 related costs. Medical Cost Ratio for the twelve months ended December 31, 2022 and 2021, include a 220 basis point and 460 basis point, respectively, unfavorable impact from COVID-19 related costs. |
(2) | The GAAP Net Loss for the twelve months ended December 31, 2022 included EBITDA related adjustments from continuing operations of $404.5 million, and over $180 million of investment impairments, restructuring costs, goodwill and intangibles impairments and other exit related costs related to discontinued operations. |
See the table at the end of this release for additional information and a reconciliation of the non-GAAP measure used in the table above.
Financial Outlook
For full year 2023, Bright Health Group is providing the following guidance and commentary:
Bright Health Group’s 2023 outlook remains consistent with the update provided in January 2023, but the company’s expectation for Revenue is now lower due to our finalized accounting treatment on certain value-based care contracts. Operating Cost expectations are unchanged, but is now forecast to be a higher percent of Revenue.
Liquidity and Going Concern
Bright Health Group noted in a Form 8-K filed this morning that during the First Quarter of 2023 the Company breached the minimum liquidity covenant of its credit facility. Bright Health has been working cooperatively with its bank group and, as described in such Form 8-K, has entered into a waiver and amendment to its credit facility which reduced the minimum liquidity requirement until April 30th. As of February 24, 2023, the Company possesses more than $150 million in non-regulated cash, nearly all of which is in cash and cash equivalents. Additionally, the Company had over $2.8 billion of additional cash and short- or long-term investments held by its regulated insurance subsidiaries as of December 31, 2022.
Bright Health Group expects to file its Annual Report on Form 10-K within the next 15 days, which will include a disclosure around substantial doubt of the Company’s ability to continue as a “going concern”. This is predicated on the Company’s ability to obtain additional capital to fund our ongoing operations over the next twelve months. The Company’s management is actively engaged with its Board of Directors and the Company’s outside advisors to find the best long-term capital structure based on the Company’s size and financial expectations.
Earnings Conference Call
As previously announced, Bright Health Group will discuss the Company’s results, strategy, and outlook on a conference call with investors at 8:00 a.m. Eastern Time today. Bright Health Group will host a live webcast of this conference call which can be accessed from the Investor Relations page of the company’s website (investors.brighthealthgroup.com). Following the call, a webcast replay will be available on the same site. This earnings release and the Form 8-K filed March 1, 2023, can be accessed on the Investor Relations page of the Company’s website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, U.S. Securities and Exchange Commission (“SEC”) filings and public conference calls and webcasts.
About Bright Health Group
Bright Health Group is a technology enabled, value-driven healthcare company that organizes and operates networks of affiliate care providers to be successful at managing population risk. We focus on serving aging and underserved consumers that have unmet clinical needs through our Fully Aligned Care Model in Florida, Texas and California, some of the largest markets in healthcare where 26% of the U.S. aging population call home. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.
Notes
† Reconciliations of projected Adjusted EBITDA and projected Adjusted Operating Cost Ratio to the most directly comparable GAAP financial measures are not provided because the Company is unable to provide such reconciliations without unreasonable effort. The inability to provide a reconciliation is due to the uncertainty and inherent difficulty predicting the occurrence, the financial impact and the periods in which the non-GAAP adjustments may be recognized. With respect to Adjusted EBITDA, these GAAP measures may include the impact of such items as interest expense, income tax expense, depreciation and amortization, impairment of goodwill or intangible assets, transaction costs, share-based compensation expense, changes in the fair value of equity securities, changes in the fair value of contingent consideration, contract termination costs, restructuring costs; and the tax effect of all such items. Historically, the Company has excluded these items from non-GAAP financial measures. With respect to Adjusted Operating Cost Ratio, these GAAP measures may include the impact of such items as stock-based compensation, changes in the fair value of contingent consideration, contract termination costs, and depreciation and amortization. The Company currently expects to continue to exclude these items in future disclosures of non-GAAP financial measures and may also exclude other items that may arise (collectively, “non-GAAP adjustments”). The decisions and events that typically lead to the recognition of non-GAAP adjustments, such as a decision to exit part of the business, are inherently unpredictable as to if or when they may occur. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
Forward-Looking Statements
Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” “outlook,” “ensure,” and other similar expressions. These forward-looking statements include any statements regarding our plans and expectations with respect to Bright Health Group, Inc. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: our ability to continue as a going concern; our ability to comply with the terms of our credit facility, including financial covenants, both during and after any waiver period, and/or obtain any additional waivers of any terms of our credit facility to the extent required; our ability to quickly and efficiently wind down our IFP businesses and MA businesses outside of California; potential disruptions to our business due to our corporate restructuring and resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our businesses offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our Care Partner’s abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to accurately estimate our medical expenses, effectively manage our costs and claims liabilities or appropriately price our products and charge premiums; our ability to obtain claims information timely and accurately; the impact of the ongoing COVID-19 pandemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage the growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions and integrate acquired businesses; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to the new risks associated with our expansion into ACO Reach; and the other factors set forth under the heading “Risk Factors” in the Company’s reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.
Bright Health Group, Inc. and Subsidiaries Consolidated Balance Sheets (in thousands, except share and per share data) (Unaudited) | |||||||
| As of December 31, | ||||||
| 2022 |
| 2021 | ||||
Assets | | | | ||||
Current assets: | | | | ||||
Cash and cash equivalents | $ | 466,325 |
| | $ | 289,283 |
|
Short-term investments |
| 13,206 |
| |
| 144,477 |
|
Accounts receivable, net of allowance of $6,098 and $3,417, respectively |
| 73,605 |
| |
| 98,882 |
|
Direct contracting performance year receivable |
| 99,181 |
|
|
| — |
|
Current assets of discontinued operations |
| 2,783,474 |
|
|
| 1,027,345 |
|
Prepaids and other current assets |
| 134,843 |
| |
| 100,213 |
|
Total current assets |
| 3,570,634 |
| |
| 1,660,200 |
|
Other assets: | | | | ||||
Long-term investments |
| 5,401 |
| |
| 18,608 |
|
Property, equipment and capitalized software, net |
| 42,596 |
| |
| 38,344 |
|
Goodwill |
| 760,078 |
| |
| 830,992 |
|
Intangible assets, net |
| 249,083 |
| |
| 336,995 |
|
Long-term assets of discontinued operations |
| — |
|
|
| 668,695 |
|
Other non-current assets |
| 37,260 |
| |
| 44,505 |
|
Total other assets |
| 1,094,418 |
| |
| 1,938,139 |
|
Total assets | $ | 4,665,052 |
| | $ | 3,598,339 |
|
Liabilities, Redeemable Noncontrolling Interests, Redeemable Preferred Stock and Shareholders’ Equity (Deficit) | | | | ||||
Current liabilities: | | | | ||||
Medical costs payable | $ | 411,753 |
| | $ | 263,187 |
|
Accounts payable |
| 67,854 |
| |
| 57,888 |
|
Unearned revenue |
| 242 |
| |
| 2,585 |
|
Short-term borrowings |
| 303,947 |
|
|
| 155,000 |
|
Current liabilities of discontinued operations |
| 2,783,474 |
|
|
| 1,696,040 |
|
Other current liabilities |
| 121,424 |
| |
| 108,849 |
|
Total current liabilities |
| 3,688,694 |
| |
| 2,283,549 |
|
Other liabilities |
| 36,673 |
| |
| 41,263 |
|
Total liabilities |
| 3,725,367 |
| |
| 2,324,812 |
|
Redeemable noncontrolling interests |
| 219,758 |
| |
| 128,407 |
|
Redeemable Series A preferred stock, $0.0001 par value; 750,000 and — shares authorized in 2022 and 2021, respectively; 750,000 and — shares issued and outstanding in 2022 and 2021, respectively |
| 747,481 |
| |
| — |
|
Redeemable Series B preferred stock, $0.0001 par value; 175,000 shares authorized in 2022 and 2021, respectively; 175,000 and — shares issued and outstanding in 2022 and 2021, respectively |
| 172,936 |
|
|
| — |
|
Shareholders’ equity (deficit): | | | | ||||
Common stock, $0.0001 par value; 3,000,000,000 shares authorized in 2022 and 2021; 630,271,508 and 628,622,872 shares issued and outstanding in 2022 and 2021, respectively |
| 63 |
| |
| 63 |
|
Additional paid-in capital |
| 2,972,271 |
| |
| 2,861,243 |
|
Accumulated deficit |
| (3,156,395 | ) | |
| (1,700,851 | ) |
Accumulated other comprehensive (loss) income |
| (4,429 | ) | |
| (3,335 | ) |
Treasury stock, at cost, 2,522,148 shares at December 31, 2022 and 2021 |
| (12,000 | ) |
|
| (12,000 | ) |
Total shareholders’ equity (deficit) |
| (200,490 | ) | |
| 1,145,120 |
|
Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit) | $ | 4,665,052 |
| | $ | 3,598,339 |
|
Bright Health Group, Inc. and Subsidiaries Consolidated Statements of Income (Loss) (in thousands, except share and per share data) (Unaudited) | |||||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | ||||||||||||
| 2022 | | 2021 |
| 2022 | | 2021 | ||||||||
Revenue: |
|
|
|
|
|
|
| ||||||||
Premium revenue | $ | 354,842 |
| | $ | 398,150 |
|
| $ | 1,764,949 |
| | $ | 1,390,330 |
|
Direct Contracting revenue |
| 188,652 |
|
|
| — |
|
|
| 654,087 |
|
|
| — |
|
Service revenue |
| 10,731 |
| |
| 11,028 |
|
|
| 48,013 |
| |
| 42,469 |
|
Investment income |
| (2,800 | ) | |
| (28,955 | ) |
|
| (55,019 | ) | |
| 80,234 |
|
Total revenue |
| 551,425 |
| |
| 380,223 |
|
|
| 2,412,030 |
| |
| 1,513,033 |
|
Operating expenses: | | | |
|
| — |
| |
| — |
| ||||
Medical costs |
| 519,291 |
| |
| 359,820 |
|
|
| 2,206,243 |
| |
| 1,294,158 |
|
Operating costs |
| 185,731 |
| |
| 187,797 |
|
|
| 632,030 |
| |
| 527,453 |
|
Restructuring charges |
| 20,869 |
|
|
| — |
|
|
| 31,739 |
|
|
| — |
|
Goodwill impairment |
| 1,208 |
|
|
| — |
|
|
| 71,225 |
|
|
| — |
|
Intangible assets impairment |
| — |
|
|
| — |
|
|
| 42,611 |
|
|
| — |
|
Depreciation and amortization |
| 10,402 |
| |
| 9,358 |
|
|
| 50,430 |
| |
| 35,049 |
|
Total operating expenses |
| 737,501 |
| |
| 556,975 |
|
|
| 3,034,278 |
| |
| 1,856,660 |
|
Operating loss |
| (186,076 | ) | |
| (176,752 | ) |
|
| (622,248 | ) | |
| (343,627 | ) |
Interest expense |
| 6,386 |
| |
| 947 |
|
|
| 12,821 |
| |
| 7,230 |
|
Other income |
| — |
| — |
| — |
| — |
| (784 | ) | — |
| (1,226 | ) |
Loss from continuing operations before income taxes |
| (192,462 | ) | |
| (177,699 | ) |
|
| (634,285 | ) | |
| (349,631 | ) |
Income tax (benefit) expense |
| (4,228 | ) | |
| (8,295 | ) |
|
| 3,680 |
| |
| (26,521 | ) |
Net loss from continuing operations |
| (188,234 | ) | |
| (169,404 | ) |
|
| (637,965 | ) | |
| (323,110 | ) |
Loss from discontinued operations, net of tax |
| (480,327 | ) |
|
| (646,761 | ) |
|
| (721,915 | ) |
|
| (855,255 | ) |
Net loss | $ | (668,561 | ) |
| $ | (816,165 | ) |
| $ | (1,359,880 | ) |
| $ | (1,178,365 | ) |
Net earnings from continuing operations attributable to noncontrolling interests | $ | (11,012 | ) | | $ | (1,143 | ) |
| $ | (95,664 | ) | | $ | (6,497 | ) |
Series A preferred stock dividend accrued | $ | (9,806 | ) |
| $ | — |
|
| $ | (37,889 | ) |
| $ | — |
|
Series B preferred stock dividend accrued | $ | (1,798 | ) |
| $ | — |
|
| $ | (1,798 | ) |
|
| ||
Net loss attributable to Bright Health Group, Inc. common shareholders | $ | (691,177 | ) | | $ | (817,308 | ) |
| $ | (1,495,231 | ) | | $ | (1,184,862 | ) |
|
|
|
|
|
|
|
| ||||||||
Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders |
|
|
|
|
|
|
| ||||||||
Continuing operations |
| (0.34 | ) | |
| (0.27 | ) |
|
| (1.23 | ) | |
| (0.84 | ) |
Discontinued operations |
| (0.76 | ) |
|
| (1.03 | ) |
|
| (1.15 | ) |
|
| (2.18 | ) |
Basic and diluted loss per share |
| (1.10 | ) |
|
| (1.30 | ) |
|
| (2.38 | ) |
|
| (3.02 | ) |
Bright Health Group, Inc. and Subsidiaries Consolidated Statements of Cash Flows (in thousands) (Unaudited) | |||||||
| Twelve Months Ended December 31, | ||||||
| 2022 |
| 2021 | ||||
Cash flows from operating activities: | | | | ||||
Net loss | $ | (1,359,880 | ) | | $ | (1,184,862 | ) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
| ||||
Depreciation and amortization |
| 50,575 |
| |
| 35,484 |
|
Impairment of intangibles |
| 49,331 |
|
|
| — |
|
Impairment of goodwill |
| 75,372 |
|
|
| — |
|
Share-based compensation |
| 109,713 |
| |
| 68,423 |
|
Deferred income taxes |
| 2,027 |
| |
| (25,654 | ) |
Unrealized gain on equity securities |
| 55,449 |
|
|
| (80,231 | ) |
Impairment of investments |
| 67,723 |
|
|
| — |
|
Other, net |
| 17,077 |
| |
| 20,254 |
|
Changes in assets and liabilities, net of acquired assets and liabilities: |
| | | ||||
Accounts receivable |
| 28,787 |
| |
| (32,941 | ) |
Direct Contracting receivable |
| (99,181 | ) |
|
| — |
|
Other assets |
| (14,744 | ) | |
| (143,463 | ) |
Medical cost payable |
| 279,563 |
| |
| 475,461 |
|
Risk adjustment payable |
| 1,012,720 |
| |
| 742,075 |
|
Accounts payable and other liabilities |
| 2,727 |
| |
| 192,611 |
|
Unearned revenue |
| (42,760 | ) | |
| 14,902 |
|
Net cash provided by operating activities |
| 234,499 |
| |
| 82,059 |
|
Cash flows used in investing activities: |
|
|
| ||||
Purchases of investments |
| (1,457,444 | ) | |
| (1,017,588 | ) |
Proceeds from sales, paydown, and maturities of investments |
| 1,055,479 |
| |
| 926,901 |
|
Purchases of property and equipment |
| (27,448 | ) | |
| (30,414 | ) |
Business acquisitions, net of cash acquired |
| (310 | ) | |
| (431,791 | ) |
Net cash used in investing activities |
| (429,723 | ) | |
| (552,892 | ) |
Cash flows from financing activities: | | | | ||||
Proceeds from issuance of preferred stock |
| 920,417 |
|
|
| — |
|
Proceeds from issuance of common stock |
| 1,315 |
| |
| 11,390 |
|
Net proceeds from short-term borrowings |
| 148,947 |
|
|
| 155,000 |
|
Payments for debt issuance costs |
| — |
|
|
| (3,391 | ) |
Distribution to noncontrolling interest holders |
| (4,311 | ) |
|
| — |
|
Proceeds from IPO |
| — |
|
|
| 887,328 |
|
Payments for IPO offering costs |
| — |
| |
| (6,686 | ) |
Net cash provided by financing activities |
| 1,066,368 |
| |
| 1,043,641 |
|
Net increase in cash and cash equivalents |
| 871,144 |
| |
| 572,808 |
|
Cash and cash equivalents – beginning of year |
| 1,061,179 |
| |
| 488,371 |
|
Cash and cash equivalents – end of year | $ | 1,932,323 |
| | $ | 1,061,179 |
|
Bright Health Group, Inc. and Subsidiaries Segment Information (in thousands) (Unaudited) | |||||||||||||||
Bright HealthCare | Three Months Ended |
| Twelve Months Ended | ||||||||||||
($ in thousands) | December 31, |
| December 31, | ||||||||||||
Statements of income (loss) data: | 2022 | | 2021 |
| 2022 | | 2021 | ||||||||
|
|
|
|
|
|
|
| ||||||||
Bright HealthCare: |
|
|
|
|
|
|
| ||||||||
Revenue: |
|
|
|
|
|
|
| ||||||||
Premium revenue |
| 393,200 |
|
|
| 367,910 |
|
|
| 1,652,045 |
|
|
| 1,297,273 |
|
Investment income |
| 328 |
|
|
| (185 | ) |
|
| 410 |
|
|
| (80 | ) |
Total revenue |
| 393,528 |
|
|
| 367,725 |
|
|
| 1,652,455 |
|
|
| 1,297,193 |
|
Operating expenses |
|
|
|
|
|
|
| — |
| ||||||
Medical costs |
| 393,406 |
|
|
| 356,591 |
|
|
| 1,550,934 |
|
|
| 1,262,407 |
|
Operating costs |
| 59,715 |
|
|
| 70,491 |
|
|
| 187,191 |
|
|
| 189,648 |
|
Goodwill impairment |
| — |
|
|
| — |
|
|
| 70,017 |
|
|
| — |
|
Depreciation and amortization |
| 4,411 |
|
|
| 4,342 |
|
|
| 17,702 |
|
|
| 14,245 |
|
Total operating expenses |
| 457,532 |
|
|
| 431,424 |
|
|
| 1,826,289 |
|
|
| 1,466,300 |
|
Operating loss | $ | (64,004 | ) |
| $ | (63,699 | ) |
| $ | (173,834 | ) |
| $ | (169,107 | ) |
|
|
|
|
|
|
|
| ||||||||
Medical Cost Ratio (MCR) |
| 100.1 | % |
|
| 96.9 | % |
|
| 93.9 | % |
|
| 97.3 | % |
Consumer Care | Three Months Ended |
| Twelve Months Ended | ||||||||||||
($ in thousands) | December 31, |
| December 31, | ||||||||||||
Statements of income (loss) data: | 2022 | | 2021 |
| 2022 | | 2021 | ||||||||
|
|
|
|
|
|
|
| ||||||||
Consumer Care: |
|
|
|
|
|
|
| ||||||||
Revenue: |
|
|
|
|
|
|
| ||||||||
Premium revenue | $ | 168,063 |
|
| $ | 116,418 |
|
| $ | 1,141,936 |
|
| $ | 338,391 |
|
Direct Contracting revenue |
| 188,652 |
|
|
| — |
|
|
| 654,087 |
|
|
| — |
|
Service revenue |
| 10,731 |
|
|
| 11,028 |
|
|
| 48,013 |
|
|
| 42,469 |
|
Investment income |
| (3,128 | ) |
|
| (28,770 | ) |
|
| (55,429 | ) |
|
| 80,314 |
|
Total revenue |
| 364,318 |
|
|
| 98,676 |
|
|
| 1,788,607 |
|
|
| 461,174 |
|
Operating expenses: |
|
|
|
|
| — |
|
|
| — |
| ||||
Medical costs |
| 476,316 |
|
|
| 221,143 |
|
|
| 1,844,578 |
|
|
| 432,318 |
|
Operating costs |
| 57,799 |
|
|
| 39,155 |
|
|
| 189,586 |
|
|
| 125,444 |
|
Goodwill impairment |
| 1,208 |
|
|
| — |
|
|
| 1,208 |
|
|
| — |
|
Intangible assets impairment |
| — |
|
|
| — |
|
|
| 42,611 |
|
|
| — |
|
Depreciation and amortization |
| 3,680 |
|
|
| 3,971 |
|
|
| 24,252 |
|
|
| 18,333 |
|
Total operating expenses |
| 539,003 |
|
|
| 264,269 |
|
|
| 2,104,351 |
|
|
| 576,095 |
|
Operating loss | $ | (174,685 | ) |
| $ | (165,593 | ) |
| $ | (315,744 | ) |
| $ | (114,921 | ) |
|
|
|
|
|
|
|
| ||||||||
Non-GAAP Financial Measures
We use the non-GAAP financial measure Adjusted EBITDA. We define Adjusted EBITDA as Net Loss excluding loss from discontinued operations, Interest Expense, Income Taxes, Depreciation and Amortization, adjusted for the impact of impairment of goodwill or intangible assets, acquisition and financing-related transaction costs, share-based compensation, changes in the fair value of contingent consideration, changes in the fair value of equity securities, contract termination costs and restructuring costs. This non-GAAP measure has been presented in this quarterly Earnings Release as a supplemental measure of financial performance that is not required by or presented in accordance with GAAP because we believe it assists management and investors in comparing our operating performance across reporting periods on a consistent basis by excluding and including items that we do not believe are indicative of our core operating performance. Management believes this measure is useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.
Adjusted EBITDA is not a recognized term under GAAP and should not be considered as an alternative to Net Income (Loss) as a measure of financial performance or any other performance measure derived in accordance with GAAP. Additionally, Adjusted EBITDA is not intended to be a measure of free cash flow available for management’s discretionary use as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentation of Adjusted EBITDA has limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
The following table provides a reconciliation of net loss to Adjusted EBITDA for the periods presented:
| Three Months Ended |
| Twelve Months Ended | ||||||||||||
($ in thousands) | 2022 |
| 2021 |
| 2022 |
| 2021 | ||||||||
Net loss | $ | (668,561 | ) |
| $ | (813,375 | ) |
| $ | (1,359,880 | ) |
| $ | (1,178,365 | ) |
Loss from discontinued operations (a) |
| 480,327 |
|
|
| 646,762 |
|
|
| 721,915 |
|
|
| 855,255 |
|
EBITDA adjustments from continuing operations: |
|
|
|
|
|
|
| ||||||||
Interest expense |
| 6,386 |
|
|
| 948 |
|
|
| 12,821 |
|
|
| 7,230 |
|
Income tax (benefit) expense |
| (4,228 | ) |
|
| (8,296 | ) |
|
| 3,680 |
|
|
| (26,521 | ) |
Depreciation and amortization |
| 10,402 |
|
|
| 9,358 |
|
|
| 50,430 |
|
|
| 35,049 |
|
Goodwill impairment |
| 1,208 |
|
|
| — |
|
|
| 71,225 |
|
|
| — |
|
Intangible assets impairment |
| — |
|
|
| — |
|
|
| 42,611 |
|
|
| — |
|
Transaction costs (b) |
| 1,407 |
|
|
| (4,854 | ) |
|
| 1,661 |
|
|
| 2,064 |
|
Share-based compensation expense (c) |
| 32,450 |
|
|
| 25,190 |
|
|
| 109,713 |
|
|
| 68,423 |
|
Change in fair value of equity securities (d) |
| 10,892 |
|
|
| 28,780 |
|
|
| 80,231 |
|
|
| (80,231 | ) |
Change in fair value of contingent consideration (e) |
| 332 |
|
|
| (5,584 | ) |
|
| 332 |
|
|
| (4,221 | ) |
Contract termination costs (f) |
| — |
|
|
| — |
|
|
| 1,241 |
|
|
| — |
|
Restructuring costs (g) |
| 20,869 |
|
|
| — |
|
|
| 30,531 |
|
|
| — |
|
EBITDA adjustments from continuing operations |
| 79,718 |
|
|
| 45,542 |
|
|
| 404,476 |
|
|
| 1,793 |
|
Adjusted EBITDA | $ | (108,516 | ) |
| $ | (121,071 | ) |
| $ | (233,489 | ) |
| $ | (321,317 | ) |
(a) | Beginning in fourth quarter of 2022, Adjusted EBITDA excludes the impact of discontinued operations. The comparable period in 2021 has been recast to exclude these impacts. Represents losses associated with the Commercial business segment that we exited at the end of 2022. The loss from discontinued operations includes over $165 million and over $180 million of investment impairments, restructuring costs, goodwill and intangibles impairments and other exit related costs for the three and twelve months ended December 31, 2022, respectively. |
(b) | Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees directly relating to business combinations and certain costs associated with our initial public offering. These costs can vary from period to period and impact comparability, and we do not believe such transaction costs reflect the ongoing performance of our business. |
(c) | Represents non-cash compensation expense related to stock option and restricted stock unit award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards. |
(d) | Beginning in 2022, Adjusted EBITDA excludes the impact of changes in unrealized gains and losses on equity securities. The comparable period in 2021 has been recast to exclude changes in unrealized gains and losses on equity securities. |
(e) | Represents the non-cash change in fair value of contingent consideration from business combinations, which is remeasured at fair value each reporting period. |
(f) | Represents amounts paid for early termination of existing vendor contracts. |
(g) | Restructuring costs represent severance costs as part of a workforce reduction in 2022 and impairment of certain long-lived assets relating to our decision to exit the Commercial business for the 2023 plan year. |
| Last Trade: | US$5.14 |
| Daily Change: | 0.09 1.78 |
| Daily Volume: | 9,196 |
| Market Cap: | US$42.560M |
October 30, 2024 August 07, 2024 May 08, 2024 March 06, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
